MA26681A1 - Composes pyrazine - Google Patents

Composes pyrazine

Info

Publication number
MA26681A1
MA26681A1 MA25746A MA25746A MA26681A1 MA 26681 A1 MA26681 A1 MA 26681A1 MA 25746 A MA25746 A MA 25746A MA 25746 A MA25746 A MA 25746A MA 26681 A1 MA26681 A1 MA 26681A1
Authority
MA
Morocco
Prior art keywords
pyrazine compounds
pyrazine
compounds
Prior art date
Application number
MA25746A
Other languages
English (en)
Inventor
Cox Brian
Wild Deborah
Patrick Healy Mark
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26681A1 publication Critical patent/MA26681A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25746A 1998-08-28 1999-08-27 Composes pyrazine MA26681A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818881.6A GB9818881D0 (en) 1998-08-28 1998-08-28 Compounds

Publications (1)

Publication Number Publication Date
MA26681A1 true MA26681A1 (fr) 2004-12-20

Family

ID=10838055

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25746A MA26681A1 (fr) 1998-08-28 1999-08-27 Composes pyrazine

Country Status (15)

Country Link
US (2) US6503909B1 (fr)
EP (1) EP1107960A1 (fr)
JP (1) JP2002523499A (fr)
KR (1) KR20010079696A (fr)
CN (1) CN1324349A (fr)
AU (1) AU5624999A (fr)
BR (1) BR9913183A (fr)
CA (1) CA2341543A1 (fr)
CO (1) CO5130006A1 (fr)
GB (1) GB9818881D0 (fr)
MA (1) MA26681A1 (fr)
PE (1) PE20001022A1 (fr)
TR (1) TR200100603T2 (fr)
TW (1) TW429255B (fr)
WO (1) WO2000012488A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500653A1 (fr) * 2000-02-16 2005-01-26 Neurogen Corporation Arylpyrazines substituées
CN1231473C (zh) 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
GB0010971D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Process
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2484209C (fr) * 2002-05-03 2013-06-11 Exelixis, Inc. Modulateurs de proteine kinase et procedes d'utilisation
EP1554258A1 (fr) 2002-08-20 2005-07-20 Neurogen Corporation 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf
US7381409B2 (en) * 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
EP1731609A4 (fr) * 2004-03-30 2010-04-07 Genomidea Inc INHIBITEUR DE L'EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L'INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2460828A3 (fr) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Anticorps et diagnostic
WO2008061013A2 (fr) * 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
KR102918161B1 (ko) * 2022-03-16 2026-01-28 (주)아름테라퓨틱스 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575975A (en) * 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3544568A (en) * 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.

Also Published As

Publication number Publication date
CN1324349A (zh) 2001-11-28
TW429255B (en) 2001-04-11
US6503909B1 (en) 2003-01-07
US20030022904A1 (en) 2003-01-30
WO2000012488A1 (fr) 2000-03-09
BR9913183A (pt) 2001-05-15
CO5130006A1 (es) 2002-02-27
CA2341543A1 (fr) 2000-03-09
TR200100603T2 (tr) 2001-07-23
KR20010079696A (ko) 2001-08-22
PE20001022A1 (es) 2000-10-16
JP2002523499A (ja) 2002-07-30
AU5624999A (en) 2000-03-21
EP1107960A1 (fr) 2001-06-20
GB9818881D0 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
DE69818643T2 (de) Pyrazin-Verbindungen
FR09C0030I2 (fr) Composes thrombopoietiques
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
DE69835302D1 (de) Tintenbehälternachfüllsystem
NO20011745L (no) Forbindelser
EP1076337A4 (fr) Enregistreur-lecteur
ID23761A (id) Trisiklik tersubstitusi
ID27004A (id) Senyawa-senyawa kalsilitik
EP1087957A4 (fr) Composes auto-inducteurs
ID23219A (id) Trisiklik tersubstitusi
NO20006662L (no) Fluorfenylresin-forbindelser
MA26587A1 (fr) Composes de triazine
FI980735A0 (fi) Foerfarande foer hantering av foerdroejning
DE69913027D1 (de) Verdampfer
DE69938388D1 (de) Empfänger
DE59911610D1 (de) Substituierte benzoylcyclohexandione
EP1105133A4 (fr) Composes tricycliques
ATE303996T1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
NO980270L (no) Trekkanordning
ATA32198A (de) Beschlag
DE69838138D1 (de) Empfänger
FR2782553B1 (fr) Evaporateur
DE59911430D1 (de) Zungenverbindung